Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orchestra Therapeutics is discontinuing its HIV vaccine development program. Analysis of data from a clinical trial did not show a clear advantage of the company's second generation HIV vaccine, IR103, over its original whole-killed HIV vaccine, Remune.
Subscribe to our email newsletter
70 patients took part in the 52 week trial in Europe and Canada.
Although interim analysis of patients in this trial at 36 weeks suggested a trend toward stabilization of CD4+ counts in HAART naive patients vaccinated with Remune or IR103, this trend was not observed at week 52.
“While recognizing that the sample size is too small to achieve statistical significance, these results are, nonetheless, less than we had expected,” said Joseph F. O’Neill, president and CEO of Orchestra Therapeutics. “Our company does not have the resources to move this program forward at this time.”
Dr O’Neill also reported that Orchestra has contracted with PharmaBioSource Realty, to act as a broker to sell its HIV vaccine production facility located in King of Prussia, Pennsylvania. “Selling the assets of this facility will bring new capital into the company, help us to further reduce our burn rate, and thereby strengthen Orchestra’s potential to emerge as the world’s leading autoimmune immunotherapy company in the months and years ahead,” he claims.